Haney et al. report many studies on the use of EVs-carriers for particular therapeutic agents, such as paclitaxel and doxorubicin for the treatment of pulmonary metastatic cancer and triple-negative breast cancer, and also catalase and tripeptidyl-peptidase-1 (TPP1) for the treatment of Parkinson’s disease [75]. This evidence concerns the gene TPP1 and Parkinson disease.